(NASDAQ: CLGN) Collplant Biotechnologies's forecast annual revenue growth rate of 150% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 54.58%, and it is also forecast to beat the US market's average forecast revenue growth rate of 16.62%.
Collplant Biotechnologies's revenue in 2026 is $2,371,000.On average, 4 Wall Street analysts forecast CLGN's revenue for 2026 to be $103,345,864, with the lowest CLGN revenue forecast at $25,093,892, and the highest CLGN revenue forecast at $185,874,041. On average, 4 Wall Street analysts forecast CLGN's revenue for 2027 to be $142,651,093, with the lowest CLGN revenue forecast at $31,367,365, and the highest CLGN revenue forecast at $260,080,264.
In 2028, CLGN is forecast to generate $323,199,083 in revenue, with the lowest revenue forecast at $244,639,839 and the highest revenue forecast at $403,294,689.